Form 4 for CRL Charles River Laboratories
Accepted 2023-08-14 00:00:00 ET · period of report 2023-08-10 · accession 0001127602-23-022488 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-14 | 2023-08-10 | CRL | Barbo William D | CCO, Corp. Executive VP | M - OptEx | $144.67 | +5,511 | 9,103 | +153% | +$797.3K |
| D | 2023-08-14 | 2023-08-10 | CRL | Barbo William D | CCO, Corp. Executive VP | S - Sale+OE | $217.24 | -5,763 | 3,592 | -62% | -$1.25M |
| D | 2023-08-14 | 2023-08-10 | CRL | Barbo William D | CCO, Corp. Executive VP | M - OptEx | $0.00 | -5,511 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-10 | M | A | 5,511 | $144.67 | 9,103 | D | — | — | |
| 2 | Common | Common Stock | 2023-08-10 | S | D | 5,763 | $217.24 | 3,592 | D | — | — | |
| 3 | Derivative | Stock Options (Right to Buy) | 2023-08-10 | M | D | 5,511 | $0.00 | 0 | D | $144.67 · 2020-02-22 to 2024-02-22 | 5,511 Common Stock |